APUS Dividende : Apimeds Pharmaceuticals US Inc Analyse du rendement



Dividendes

APUS Dividendes

Apimeds Pharmaceuticals US Inc

0%

$0

À la fermeture : May 05, 16:00:00 GMT-4

0%

$0

Pré-Marché: May 06, 07:44:15 GMT-4

Aperçu Prévision Gagner Dividendes Comptes financiers

Statistiques clés

Clôture préc.

Prix d'ouverture

Plage de la journée

Plage de 52 semaines

Volume

Volume moyen

Rendement en dividend

BPA (TTM)

Capitalisation boursière

Qu’est-ce que APUS ?

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.